FIELD: biotechnology; medicine; agriculture.
SUBSTANCE: invention refers to genetic engineering and can be used in biotechnology, medicine and agriculture to develop gene therapy preparations. Disclosed is a genotyping DNA vector based on the VTvaf17 gene-vector DNA vector carrying a target gene selected from a group of genes ANG, ANGPT1, VEGFA, FGF1, HIF1α, HGF, SDF1, KLK4, PDGFC, PROK1, PROK2, to increase level of expression of this target gene in human body and animals. Gene therapy DNA vector VTvaf17-ANG, or VTvaf17-ANGPT1, or VTvaf17-VEGFA, or VTvaf17-FGF1, or VTvaf17-HIF1α, or VTvaf17-HGF, or VTvaf17-SDF1, or VTvaf17-KLK4, or VTvaf17-PDGFC, or VTvaf17-PROK1, or VTvaf17-PROK2 has a nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, or SEQ ID No. 5, or SEQ ID No. 6, or SEQ ID No. 7, or SEQ ID No. 8, or SEQ ID No. 9, or SEQ ID No. 10, or SEQ ID No. 11, respectively. Disclosed are method of producing said vector, using a vector to increase the level of expression of target genes, an Escherichia coli strain carrying said vector, as well as a method for production of said vector on an industrial scale.
EFFECT: invention provides the possibility of its safe application for genetic therapy of humans and animals.
28 cl, 29 dwg, 41 ex
